Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Pelvic Floor Diagnostics Market size was over USD 219.2 million in 2024 and is estimated to reach USD 466.7 million by the end of 2037, expanding at a CAGR of 6.5% during the forecast timeline, i.e., 2025-2037. In 2025, the industry size of pelvic floor diagnostics is assessed at USD 233.4 million.
Pelvic floor diagnostic is a test measure that is pivotal for the identification and management of a wide range of conditions that affect the pelvic floor. This includes pelvic pain, pelvic organ prolapse, and fecal and urinary incontinence, all of which cater to the increasing demand for the market. As stated in the October 2022 NLM article, an estimated 200,000 surgeries are performed every year in the United States for pelvic organ prolapse treatment. Besides, approximately 41% to 50% of women are found to suffer from this condition upon physical examination, and only 3% are symptomatic. Also, its incidence is expected to increase to 4.9 million by 2050, thus driving the market growth.
The development of the market is also attributed to the occurrence of chronic pelvic pain, which is caused by a complicated mixture of psychosocial, neurological, urological, gastrointestinal, and musculoskeletal conditions. According to a clinical study published by NLM in February 2023, 607 patients with the condition were evaluated to understand the pricing strategy of surgery. The study denoted that the overall cost was USD 15,750 for in-network services, USD 5,264.2 for diagnostics, and USD 8,937 per patient for the treatment procedure. Therefore, the surgery expenditure for chronic pelvic pain is USD 29,951, which is extremely expensive and effectively uplifts the market expansion globally.
Pelvic Floor Diagnostics Sector: Growth Drivers and Challenges
Growth Drivers
- Rising awareness of pelvic conditions: A surge in the occurrence of pelvic diseases is the major growth factor for the pelvic floor diagnostics market across nations. According to the March 2023 NLM article, this occurs frequently among women in the age range of 15 to 21 years. Additionally, in 85% of cases, the infection takes place due to explicitly transmitted bacteria such as Chlamydia trachomatis or Neisseria gonorrhoeae. Hence, 10% to 15% of women with either of these bacteria effectively develop pelvic disorders, thus boosting the increasing need for the market.
- Increase in the aging population: The population across nations is increasing, which is yet another factor for the upliftment of the pelvic floor diagnostics market globally. As per the 2025 United Nations data report, people aged 65 years will successfully outnumber children of 18 years of age by 2080. In addition, the global aged population is projected to increase to 2.2 billion by late 2070, and it will be 265 million for people aged 80 years by mid-2030. Therefore, the incidences of pelvic conditions will also increase among the elderly population, which enhances the demand of the market across nations.
Challenges
- Huge cost and reimbursement structure: The evolution of the pelvic floor diagnostics market is hindered by restricted compensatory policies and expensive diagnostic and treatment costs. This eventually results in financial restraint among health facilities and patients, especially in developing nations. All these factors, in turn, decrease the implementation of innovative diagnostic solutions aimed at combating the occurrence of pelvic disorders, hence causing an increase in the spread of the infection among the women population.
- Complex procedures and equipment: The different types of equipment and procedures involved in the overall treatment process are complicated, which is another challenge for the pelvic floor diagnostics market to uplift effectively. The presence of small-scale medical facilities tends to find it impossible to make investments in cutting-edge technologies associated with pelvic treatment procedures. This limits the accessibility of advanced diagnostic solutions, thus imposing a negative impact on the market expansion.
Pelvic Floor Diagnostics Market: Key Insights
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
6.5% |
|
Base Year Market Size (2024) |
USD 219.2 million |
|
Forecast Year Market Size (2037) |
USD 466.7 million |
|
Regional Scope |
|
Pelvic Floor Diagnostics Segmentation
Product Type (Instruments and Equipment, Consumables, Software)
Based on product type, the instruments and equipment segment is projected to hold the highest share of 56.8% in the pelvic floor diagnostics market by the end of the forecast period. This growth is fueled by the availability of different machines and devices such as cystoscopes, manometry devices, urodynamic systems, and ultrasound machines. These readily assist health professionals in gathering appropriate data for patient evaluation. For instance, as per an article published by Topics in Companion Animal Medicine in November 2021, the success rate of endoscopic repossession ranges between 68% to 88% with the inclusion of components such as a suction system, an endoscope, and biopsy forceps, thus driving the segment’s expansion.
Diagnostic Tests (Ultrasound Systems, Urodynamics Systems, Uroflowmetry Devices, Anal Manometry Systems, Cystoscopes, Cart/Trolley Based, Portable Bladder Ultrasound Systems, EMG)
Based on diagnostic tests, the ultrasound systems segment is expected to account for a share of 42.3% in the pelvic floor diagnostics market during the forecast timeline. This segment offers noninvasive imaging of the pelvic floor for real-time analysis of conditions such as pelvic organ prolapse or urinary incontinence, thus making these systems crucial tools. As per an article published by Continence in December 2023, the dynamic endoanal ultrasound (EAUS) acquires a complete 360-degree endoanal image and provides 100% specificity. Therefore, the availability of such ultrasound denotes a suitable opportunity for the overall market to develop.
Our in-depth analysis of the global pelvic floor diagnostics market includes the following segments:
|
Product Type |
|
|
Diagnostic Tests |
|
|
End Use |
|
|
Indication |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportPelvic Floor Diagnostics Industry - Regional Synopsis
North America Market Analysis
North America in the pelvic floor diagnostics market is anticipated to hold the largest share of 39.5% by the end of 2037. The region’s growth is fueled by the increasing occurrence of pelvic disorders among expectant mothers and a surge in health expenditure. This denotes a high consciousness of the female population regarding the diagnostics and treatment solutions in the region. Also, healthcare professionals are continuously researching and developing technology to ensure a suitable and easy procedure for undergoing surgeries.
The presence of regulatory organizations is a productive opportunity for the pelvic floor diagnostics market in the U.S. For instance, in November 2022, the U.S. FDA accelerated the acceptance of mirvetuximab soravtansine-gynx, especially for adults suffering from peritoneal, fallopian tube, and platinum-resistant epithelial ovarian cancers. Additionally, the organization also approved the VENTANA FOLR1 RxDx Assay, which is a cohort diagnostic device to select patients for the above indication. Therefore, with these approvals, the organization played a critical role in the market upliftment and expansion.
There is a huge growth opportunity for the pelvic floor diagnostics market in Canada since government and regulatory bodies operate together to promote healthy lifestyles. According to the September 2023 Government of Canada report, administrative professionals proclaimed an investment of USD 1.6 million to the Endometriosis Network Canada and the Society of Obstetricians and Gynaecologists of Canada (SOGC). The purpose was to improve awareness of endometriosis, wherein the tissue outplants outside the uterus, causing the growth of cysts and lesions around the pelvic area, thus uplifting the market demand in the country.
APAC Market Statistics
The Asia Pacific pelvic floor diagnostics market is expected to be the fastest-growing region by the end of the forecast period. This growth is fueled by the organization of awareness programs by organizations owing to the high prevalence of pelvic conditions. For instance, in December 2024, Mindray’s M-Elite program in Jakarta, co-organized by RSCM, has been a milestone in pelvic floor health advancement. This focused on the launch of a consensus statement regarding pelvic floor ultrasound standardization in South-East Asia, including 20 hospitals from Thailand, Philippines, Singapore, Malaysia, Indonesia, and China, thus bolstering the market demand.
The pelvic floor diagnostics market in India is gaining more exposure due to partnerships between international and regional organizations. For instance, in May 2024, Becton, Dickinson and Company declared its partnership with Healthians to develop cervical cancer transmission by providing a ground-breaking opportunity for women in the country to self-collect a sample in the privacy of their own homes. This is a huge development in the country, wherein women are not required to experience the social stigma for pelvic evaluation, thus a prolific opportunity for market growth.
The pelvic floor diagnostics market growth in China is increasing owing to factors including increased urbanization, a rise in the middle-class population, and an escalation in health awareness among the population. As per a clinical study published by NLM in May 2023, 504 women of childbearing age were evaluated regarding the awareness of the pelvic floor ultrasound, which is a suitable method for assessing pelvic dysfunction. The average score for practice was 16.51, 39.98 for attitudes, and 12.53 for knowledge, thereby denoting the increasing demand and expansion of the market in the region.
Companies Dominating the Pelvic Floor Diagnostics Landscape
- Alacer Biomédica
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Mui Scientific
- Stericom
- MEDICASPA
- Laborie, Inc.
- Medtronic Plc
- Medspira
- The Prometheus Group
- Diversatek, Inc.
- Becton, Dickinson and Company
- Healthians
- Photocure ASA
- Blue Earth Diagnostics
- Ambu
- Olympus Corporation
Organizations in the pelvic floor diagnostics market are increasingly focusing on strategies such as mergers and acquisitions, partnerships, and ensuring investments in research and development activities to expand their position internationally. For instance, in July 2024, Photocure ASA declared its tactical agreement with Richard Wolf GmbH to advance and commercialize a next-generation 4K LED high-definition, ecological, and flexible blue light cystoscope based on Richard Wolf’s System blue technology. The ultimate objective was to ensure innovation in blue light cystoscopy equipment internationally so that surgeons can offer patients with suitable treatment in an outpatient or surveillance setting.
Here's the list of some key players:
In the News
- In July 2024, Blue Earth Diagnostics proclaimed the results of a data analysis from the Phase 3 study, which included the utilization of FDA-approved POSLUMA injections for patients with recurrent prostate cancer.
- In October 2023, Ambu notified the CE clearance of its latest HD cystoscope, the Ambu aScope 5 Cysto HD, in combination with the full-HD endoscopy system, the Ambu aView 2 Advance, to offer urologists a single-use cystoscope for next-level imaging.
Author Credits: Radhika Pawar
- Report ID: 7626
- Published Date: May 08, 2025
- Report Format: PDF, PPT
